Fig 1.
Recurrence-free survival (RFS) and cancer-specific survival (CSS) curves for the high (≥50%) and low primary progesterone receptor (p-PgR) (<50%) groups.
RFS and CSS were significantly better in the high p-PgR group than in the low p-PgR group (RFS: P = 0.0053; CSS: P = 0.0031).
Table 1.
Survival analysis according to the Allred score and PgR staining percentage in primary tumors.
Table 2.
Survival analysis of the influence of clinicopathological variables including the preoperative endocrine prognostic index (PEPI) and PEPI combined with the primary PgR status (PEPI-P).
Fig 2.
Cumulative survival of patients with breast cancer stratified by the original preoperative endocrine prognostic index (PEPI).
(A) Recurrence-free survival (RFS) was significantly worse in the high PEPI group than in the low PEPI group (P = 0.013). (B) No significant differences were noted in cancer-specific survival (CSS) between the high and low PEPI groups (P = 0.092).
Fig 3.
Cumulative survival of patients with breast cancer stratified by our modified PEPI including the primary PgR status (PEPI-P).
Relationships of PEPI-P with (A) recurrence-free (RFS) and (B) cancer-specific survival (CSS).